Trending...
- Boston: Mayor Wu Announces 2025 Mayor's Youth Summit
- Gail Zona of Learn AI for Biz Honored with Women's Business League Industry Leader Award
- Kevin Lanouette Named Senior Vice President and General Counsel
BOSTON ~ Tectonic Therapeutic, Inc., a biotechnology company specializing in the discovery of novel GPCR-targeted therapies (G-Protein Coupled Receptors), has announced the completion of dosing of the first human cohort in its Fc-relaxin fusion program targeting the RXFP1 receptor.
Alise Reicin, MD, President and Chief Executive Officer of Tectonic Therapeutic, expressed her excitement at this milestone: "The start of our first-in-human study is a critical and exciting milestone. We look forward to seeing the potential of relaxin biology realized in patients."
Relaxin is known as a "pregnancy hormone" and is upregulated during pregnancy to help the expectant mother's cardiovascular system meet the increased demand from the developing fetus, and to remodel tissues and musculoskeletal structures involved in childbirth. It also produces a unique and diverse range of biological effects that include pulmonary and systemic vasodilation, tissue remodeling / fibrosis reversal and reduction of inflammation. This makes it a potential therapeutic agent for cardio-pulmonary diseases.
More on Boston Chron
Tectonic's TX000045 Fc-relaxin fusion protein ("TX45") is an engineered protein designed to overcome biophysical property limitations and achieve optimal pharmacokinetic, target engagement and developability properties. Following completion of dose escalation safety studies in healthy volunteers, continued development will focus on addressing areas of very high unmet need in cardio-pulmonary indications.
Tim Springer, PhD, Co-Founder of Tectonic and Latham Family Professor at Harvard Medical School and Professor of Medicine at Children's Hospital Boston commented: "TX45 could be a potentially transformative therapy for a vast number of patients with cardiovascular diseases... TX45 is exemplary of the company's ability to execute in the development of novel GPCR-targeted biologics. We look forward to future clinical programs emerging from Tectonic's platform."
Tectonic Therapeutic's announcement marks an important milestone in their efforts to develop novel GPCR-targeted therapies for cardio-pulmonary diseases using relaxin as an agonist for RXFP1 receptor activation. With their engineered protein TX45 offering potential best-in-class properties, they are hopeful that it will be able to address areas with very high unmet need in these indications.
Alise Reicin, MD, President and Chief Executive Officer of Tectonic Therapeutic, expressed her excitement at this milestone: "The start of our first-in-human study is a critical and exciting milestone. We look forward to seeing the potential of relaxin biology realized in patients."
Relaxin is known as a "pregnancy hormone" and is upregulated during pregnancy to help the expectant mother's cardiovascular system meet the increased demand from the developing fetus, and to remodel tissues and musculoskeletal structures involved in childbirth. It also produces a unique and diverse range of biological effects that include pulmonary and systemic vasodilation, tissue remodeling / fibrosis reversal and reduction of inflammation. This makes it a potential therapeutic agent for cardio-pulmonary diseases.
More on Boston Chron
- IntellaTriage Launches New Patient Engagement Service
- Momentum Stock Trading: AI-Driven by Tickeron
- IntellaTriage Launches New Patient Engagement Service
- Cascadia Global Security Launches Cascadia Off-Duty
- CathVision to Showcase Innovations at AF Symposium, Present New Science
Tectonic's TX000045 Fc-relaxin fusion protein ("TX45") is an engineered protein designed to overcome biophysical property limitations and achieve optimal pharmacokinetic, target engagement and developability properties. Following completion of dose escalation safety studies in healthy volunteers, continued development will focus on addressing areas of very high unmet need in cardio-pulmonary indications.
Tim Springer, PhD, Co-Founder of Tectonic and Latham Family Professor at Harvard Medical School and Professor of Medicine at Children's Hospital Boston commented: "TX45 could be a potentially transformative therapy for a vast number of patients with cardiovascular diseases... TX45 is exemplary of the company's ability to execute in the development of novel GPCR-targeted biologics. We look forward to future clinical programs emerging from Tectonic's platform."
Tectonic Therapeutic's announcement marks an important milestone in their efforts to develop novel GPCR-targeted therapies for cardio-pulmonary diseases using relaxin as an agonist for RXFP1 receptor activation. With their engineered protein TX45 offering potential best-in-class properties, they are hopeful that it will be able to address areas with very high unmet need in these indications.
Filed Under: Business
0 Comments
Latest on Boston Chron
- WalkerHughes Insurance Expands Footprint With Acquisition of Independent Brokers Agency LLC
- Hawk Tuah VIP Shop launches Exclusive Merchandise line for Viral Meme Fans
- Orcas Island Property Owner Returns Two Prime Waterfront Properties to the Market
- 51Fifty Rifles Unveils Precision Hunting Rifle Line for 2025
- Muench Workshops Welcomes New Partners Luke Dray and Sara Linssen, Announces Retirement of Andy Williams
- SpendMend and Yankee Alliance Partner to Revolutionize Purchased Services Management
- NuNorm Announces Stop Soldier Suicide as This Year's EQUAL Grant Recipient
- Darrin Jones: The Creative Force Behind the Trends—Raising Questions About Influence in The Weeknd's Music
- SmartBear Delivers AI-Driven Hubs to Transform Software Quality and Accelerate High-Quality Delivery
- Tenth Season of Award-Winning Love Letters Podcast by The Boston Globe focuses on the Possibility of Change
- Foresight Practitioner Conference 2025 – Dates, Venue, Speakers, And Competition Finalists Announced
- Boston Public Schools Launches New Website
- Latest Updates to Pennsylvania Medical Malpractice and Birth Injury Law
- Best Plant Varieties for Windbreaks and Shelterbelts
- Boston: Affordable Homeownership Opportunities in Dorchester: 270 Talbot Avenue
- InventHelp Inventor Develops Specially Designed Candleholder (BKC-250)
- Phyllo Wins SmartBear's Developer Visibility Award for Excellence in Collaboration and Innovation
- Genuine Hospitality, LLC Expands Leadership Team with Key Appointments
- New-and-Improved Caribbean-Food Website Dishes Out Free Ground-Shipping Offer; Affiliate Program Garnished with Generous Commission
- Boston: Mayor Michelle Wu Refiles Residential Tax Relief Legislation